Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optivate PK and Safety in Severe Haemophilia A
NCT02246881Phase 3Completed
- Sponsor
- Bio Products Laboratory
- Start
- Oct 2001
- Primary completion
- Jan 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of factor viii + von Willebrand factor in hemophilia A, sponsored by Bio Products Laboratory. Primary endpoint: Pharmacokinetic parameters for Factor VIII:C at 48 hours. Started Oct 2001; status: completed.
02
Drugs
factor viii + von Willebrand factor
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02246881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02246881.